JAGUAR HEALTH, INC. Proceeds from Notes Payable
JAGUAR HEALTH, INC. (JAGX) reported Proceeds from Notes Payable of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2024-04-01
- JAGUAR HEALTH, INC. proceeds from notes payable for the quarter ending 2022-12-31 was $0.00.
- JAGUAR HEALTH, INC. proceeds from notes payable for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- JAGUAR HEALTH, INC. proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
- JAGUAR HEALTH, INC. proceeds from notes payable for the quarter ending 2021-06-30 was $0.00.
- JAGUAR HEALTH, INC. proceeds from notes payable for fiscal 2022 was $3.98M, a 63.78% decline from fiscal 2021.
- JAGUAR HEALTH, INC. proceeds from notes payable for fiscal 2021 was $10.97M, a 10.77% decline from fiscal 2020.
- JAGUAR HEALTH, INC. proceeds from notes payable for fiscal 2020 was $12.30M, a 143.56% increase from fiscal 2019.
- JAGUAR HEALTH, INC. proceeds from notes payable for fiscal 2019 was $5.05M, a 96.89% increase from fiscal 2018.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $3.98M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $3.98M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-22 | $10.97M 10-K · filed 2022-03-11 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | $0.00 derived: sum of 2 quarters · filed 2022-08-22 | $10.97M 10-Q · filed 2021-11-17 | $22.93M derived: sum of 4 quarters · filed 2022-08-22 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-22 | $10.97M 10-Q · filed 2022-08-22 | $22.93M derived: sum of 3 quarters · filed 2022-08-22 | $22.93M derived: sum of 4 quarters · filed 2022-08-22 |
| 2021-03-31 | $10.97M 10-Q · filed 2022-05-10 | $22.93M derived: sum of 2 quarters · filed 2022-05-10 | $22.93M derived: sum of 3 quarters · filed 2022-05-10 | $22.93M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $11.95M derived: sum of 2 quarters · filed 2022-03-11 | $11.95M derived: sum of 3 quarters · filed 2022-03-11 | $12.30M 10-K · filed 2022-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | $0.00 derived: sum of 2 quarters · filed 2021-11-17 | $350.00K 10-Q · filed 2021-11-17 | $350.00K derived: sum of 4 quarters · filed 2021-11-17 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $350.00K 10-Q · filed 2021-08-13 | $350.00K derived: sum of 3 quarters · filed 2021-08-13 | $350.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $350.00K 10-Q · filed 2021-05-17 | $350.00K derived: sum of 2 quarters · filed 2021-05-17 | $350.00K derived: sum of 3 quarters · filed 2021-05-17 | $4.60M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $0.00 derived: sum of 2 quarters · filed 2021-03-31 | $4.25M derived: sum of 3 quarters · filed 2021-03-31 | $5.05M 10-K · filed 2021-03-31 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $4.25M derived: sum of 2 quarters · filed 2020-11-16 | $5.05M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $5.05M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $800.00K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $2.56M 10-K · filed 2020-04-03 | |||
| 2017-12-31 | $1.10M 10-K · filed 2019-04-10 | |||
| 2014-12-31 | $796.00K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |